May 8th 2024
A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.
Oral Rivaroxaban Reduces VTE in Outpatient Treatment of Patients With Cancer
March 9th 2019Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.
FDA Grants Priority Review to Polatuzumab Vedotin Combination for R/R DLBC
February 19th 2019The FDA granted a priority review to polatuzumab vedotin in combination with bendamustine plus rituximab (Rituxan) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
FDA Grants Umbralisib Breakthrough Designation for Marginal Zone Lymphoma
January 23rd 2019The FDA has granted umbralisib (TGR-1202) a breakthrough therapy designation for the treatment of adult patients with marginal zone lymphoma (MZL) who have received 1 prior anti-CD20 regimen, according to TG Therapeutics, Inc., the developer of the PI3K-delta inhibitor.
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
November 29th 2018The FDA has approved the first rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy.
FDA Approves Brentuximab Vedotin for Frontline CD30+ Peripheral T-Cell Lymphoma
November 16th 2018The Food and Drug Administration (FDA) has approved the use of brentuximab vedotin (Adcetris) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).
FDA Grants Breakthrough Designation to Brentuximab Vedotin for CD30+ PTCL
November 16th 2018The Food and Drug Administration (FDA) has granted a breakthrough therapy designation to brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the first-line treatment of CD30-expressing peripheral T-cell lymphoma (PTCL).
Trial Induces 'Best Ever' Survival Data Among Young Patients with Certain T-Cell Cancers
July 10th 2018Adding nelarabine to escalating-dose methotrexate increased the 4-year disease-free survival rate to 91% in pediatric and young adult patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, according to results from the phase III AALL0434 trial.
Telephone Intervention Reduces Unplanned Hospitalizations for Patients With Blood Cancers
April 30th 2015A navigator-designed, proactive, weekly, telephone support call to help patients with blood cancers manage their symptoms between appointments was able to significantly reduce unplanned hospitalizations at a Colorado cancer center.